| Ms Laura Elizabeth Emmons, CNM, IBCLC | |
|
11206 Kenilworth Avenue, Garrett Park, MD 20896 | |
| (617) 922-5917 | |
| Not Available |
| Full Name | Ms Laura Elizabeth Emmons |
|---|---|
| Gender | Female |
| Speciality | Registered Nurse - Lactation Consultant |
| Location | 11206 Kenilworth Avenue, Garrett Park, Maryland |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518017227 | NPI | - | NPPES |
| 2934898 | Other | MA | CIGNA |
| AA12919 | Other | MA | HPHC |
| 0700622 | Medicaid | MA | |
| HV0305 | Other | MA | BCBS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | RN1016029 (District Of Columbia) | Secondary |
| 163WL0100X | Registered Nurse - Lactation Consultant | L-89049 (Maryland) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Laura Elizabeth Emmons, CNM, IBCLC Po Box 53, Garrett Park, MD 20896 Ph: (617) 922-5917 | Ms Laura Elizabeth Emmons, CNM, IBCLC 11206 Kenilworth Avenue, Garrett Park, MD 20896 Ph: (617) 922-5917 |
News Archive
"President Bush stated this week that he intends to veto pending legislation that would reauthorize the State Children's Health Insurance Program (SCHIP), which is set to expire Sept. 30. The bill would extend health coverage to approximately 4 million uninsured children and continue providing coverage to 6 million children.
A phase III study examining whether messenger (m)RNA expression correlated with sensitivity or resistance to chemotherapy did not confer a statistically significant advantage in overall survival for patients with resected stage II-III non-small cell lung cancer (NSCLC), according to research presented at the International Association for the Study of Lung Cancer World Conference on Lung Cancer.
Cervical cancer is the third most common cancer in women worldwide, but most American women can prevent it by being screened with tests that detect human papillomaviruses (HPV).
The Montreal Heart Institute today announced the start of the Phase 2 CHI-SQUARE (Can HDL Infusions Significantly QUicken Atherosclerosis REgression?) study of CER-001 in patients with acute coronary syndrome (ACS), in collaboration with Cerenis Therapeutics, a biopharmaceutical company developing novel high-density lipoprotein (HDL) therapies to treat cardiovascular and metabolic diseases.
› Verified 7 days ago